CJC-1295 research guide for Tsogni. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Tsogni looking to source CJC-1295, the key fact to understand is that this compound moves through online research channels. This matters because CJC-1295 quality differs enormously across the market — from pharmaceutical-grade 99%+ purity to material with significant impurity issues — and the vendor is the entire quality system. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis containing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. This guide takes Tsogni researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Tsogni studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Buying CJC-1295: Quality Markers to Look For
Before assessing any particular supplier, establish a quality benchmark — so you can identify whether a supplier meets the standard. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. The combination of community consensus and independent COA review is the gold standard for CJC-1295 sourcing — community feedback surfaces systemic problems invisible in one transaction, and vice versa. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Tsogni
COA-verified · International tracking · Research grade
CJC-1295 is available for research use only and is not approved for human use by the FDA or comparable health authorities — all information here is for educational purposes only. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers running multi-compound protocols with CJC-1295 should review the available literature for documented interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
